The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 22, 2008
Filed:
Jan. 10, 2002
Hanns-martin Schmidt, Köln, DE;
Ludger Altrogge, Pulheim, DE;
Dietmar Lenz, Köln, DE;
Gudula Riemen, Langenfeld, DE;
Helmut Brosterhus, Kirchundern, DE;
Elke Lorbach, Köln, DE;
Juliana Helfrich, Köln, DE;
Katharina Hein, Köln, DE;
Marion Gremse, Köln, DE;
Tatjana Males, Hilden, DE;
Rainer Christine, Köln, DE;
Gregor Siebenkotten, Frechan-Königsdorf, DE;
Bodo Ortmann, Köln, DE;
Tamara Turbanski, Wiehl, DE;
Andreas Klaes, Köln, DE;
Hanns-Martin Schmidt, Köln, DE;
Ludger Altrogge, Pulheim, DE;
Dietmar Lenz, Köln, DE;
Gudula Riemen, Langenfeld, DE;
Helmut Brosterhus, Kirchundern, DE;
Elke Lorbach, Köln, DE;
Juliana Helfrich, Köln, DE;
Katharina Hein, Köln, DE;
Marion Gremse, Köln, DE;
Tatjana Males, Hilden, DE;
Rainer Christine, Köln, DE;
Gregor Siebenkotten, Frechan-Königsdorf, DE;
Bodo Ortmann, Köln, DE;
Tamara Turbanski, Wiehl, DE;
Andreas Klaes, Köln, DE;
Amaxa AG, , DE;
Abstract
The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals. The present inventions also includes corresponding pharmaceutical preparations, especially for use in gene therapy as well as the use of such transfection agents as component in kits.